4G Wireless Evolution

Supernus to Announce Third Quarter 2021 Financial Results and Host Conference Call on November 3, 2021
4gwe Logo
4GWE Launches New Sites: WiMAX | LTE | WIRELESS BACKHAUL | Broadband Stimulus


WiMAX Reports

TMCNet:  Supernus to Announce Third Quarter 2021 Financial Results and Host Conference Call on November 3, 2021

[October 27, 2021]

Supernus to Announce Third Quarter 2021 Financial Results and Host Conference Call on November 3, 2021

ROCKVILLE, Md., Oct. 27, 2021 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Company expects to report financial and business results for the third quarter of 2021 after the market closes on Wednesday, November 3, 2021.

Jack Khattar, President and CEO, and Tim Dec, Senior Vice President and CFO, will host a conference call to present the third quarter 2021 financial and business results on Wednesday, November 3, 2021 at 4:30 p.m. ET. Following management’s prepared remarks and discussion of business results, the call will be open for questions.

A live webcast will be available at www.supernus.com.

Please refer to the information below for conference call dial-in information. Callers should dial in approximately 10 minutes prior to the start of the call.

Conference dial-in:(877) 288-1043
International dial-in:(970) 315-0267
Conference ID:7595459
Conference Call Name:Supernus Pharmaceuticals Third Quarter 2021 Results Conference Call

Following the live call, a replay will be available on the Company’s website, www.supernus.com, in the Investor Relations section. The webcast will be available on the Company’s website for 60 days following the live call.

About Supernus Pharmaceuticals, Inc.

Supernus Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases.

Our diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, ADHD, hypomobility in Parkinson’s disease, cervical dystonia and chronic sialorrhea. We are developing a broad range of novel CNS product candidates including new potential treatments for hypomobility in Parkinson’s disease, epilepsy, depression and rare CNS disorders.

For more information, please visit www.supernus.com.

CONTACTS:

Jack A. Khattar, President and CEO
Tim Dec, Senior Vice President and CFO
Supernus Pharmaceuticals, Inc.
Tel: (301) 838-2591

or

INVESTOR CONTACT:
Peter Vozzo
ICR Westwicke
Office: (443) 213-0505
Mobile: (443) 377-4767
Email: peter.vozzo@westwicke.com


Primary Logo


[ Back To www.mobilitytechzone.com\LTE's Homepage ]




Free 4GWE eNewsletter




General Info

Technology Marketing Corporation,
2 Trap Falls Road Suite 106, Shelton, CT 06484 USA
Ph: 800-243-6002, 203-852-6800; Fx: 203-853-2845
General comments: tmc@tmcnet.com. Comments about this site: webmaster@tmcnet.com.
Technology Marketing Corp. © 2021 Copyright.
© Technology Marketing Corp. © 2021 Copyright | Privacy Policy | Sitemap | Visit other TMC Interactive sites